A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

NCT05612581 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: VIR-3434
DRUG: VIR-2218
DRUG: TDF
DRUG: PEG-IFNα

Sponsor

Vir Biotechnology, Inc.